Hidradenitis Suppurativa
Novartis’ Cosentyx Clinches First Approval for Hidradenitis Suppurativa Treatment
Anika Sharma
Novartis’ Cosentyx has gained an early lead in the field of hidradenitis suppurativa (HS), a painful skin condition, potentially giving ...
Anaptys reports positive results for its rare skin disease drug and seeks a partner for commercialization
Anika Sharma
AnaptysBio has unveiled promising phase 3 data for its rare skin disease drug candidate, indicating a potential challenge to Boehringer ...
UCB’s psoriasis drug application overcomes manufacturing hurdle but hits another FDA delay
Anika Sharma
After facing delays related to manufacturing issues, UCB’s psoriasis medication, bimekizumab, is awaiting the next steps in its FDA review ...
European Commission Approves COSENTYX as First and Only IL-17A Inhibitor for Hidradenitis Suppurativa
SG Tylor
Source: Novartis On June 1, 2023, Novartis announced that the European Commission (EC) has granted approval for the use of ...
